Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...